GT Biopharma shares surge 43.19% intraday on progress in Phase 1 trial for GTB-3650 and upcoming IND submission for GTB-5550.

GT Biopharma surged 43.19% intraday after reporting positive clinical updates and regulatory progress. The company advanced its Phase 1 trial for GTB-3650 to Cohort 4 at 10 µg/kg/day, with the next update expected in Q1 2026, and plans to submit an IND application for GTB-5550 targeting B7H3-expressing solid tumors by late December 2025 or January 2026. Management highlighted GTB-3650’s favorable safety profile and competitive advantages in immune activation, while reduced R&D expenses and a $2.6 million cash position, sufficient to fund operations until Q1 2026, added to investor optimism. These developments, emphasizing clinical progress and near-term regulatory milestones, drove the sharp intraday rally.